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• The blood cancers leukaemia, lymphoma and myeloma are expected to cause the deaths of > 55,000 people in the US in 2017. New immunological approaches afford great promise for improved therapies.
• Here, we describe novel high throughput live-cell image-based assays for immune cell activation and killing of blood cancer cells that are geared towards screening for new treatments for these malignancies.
• The data examples illustrate how continuous live-cell analysis can be used with suspension cells, to provide both additional biological insight (full time-courses, clustering information, morphology) and enhanced productivity (automation, miniaturisation) compared to other techniques.
• We believe this approach will be a valuable addition to the technology toolbox for academic and industrial immuno-oncology researchers.
Overview % Confluence as a measure of cell proliferation
• Coating of plates with Poly-Lornithine (PLO) facilitates uniform distribution of cells within each well.
• Fibronectin is also suitable for most cell types but may enhance cell proliferation per se.
• Yellow = phase confluence mask
• Cell proliferation, quantified as % confluence with IncuCyte correlates with direct cell counting (Coulter counter, Scepter™) and ATP bioluminescence.
• WIL2-NS cells were plated at the indicated densities on PLO-coated 96-well plates.
Non-adherent cell assay methodology
Plate-coatings: impact on distribution of cells

Growth curves
L-kynurenine inhibits T-cell proliferation & clustering
• L-kynurenine (L-kyn) is a metabolite formed from the catabolism of L-tryptophan by the enzymes IDO and TDO.
• Some cancers increase L-kyn production in a bid to block antigen-driven T-cell proliferation and induce T-cell death, thus allowing cancer cells to escape immune surveillance.
• Inhibitors of IDO and/or TDO are therefore promising therapeutic targets for the treatment of cancer.
• Note the clear concentration-related inhibition of IL-2/anti-CD3 activated T-cell proliferation and clustering with the addition of exogenous L-kyn, over time.
• Time-course profiles enabled area under curve (AUC) analysis and generation of concentration-response curves from which IC 50 values for inhibition of proliferation and clustering were determined.
Proliferation Cluster formation
Antibody-dependent cell-mediated cytotoxicity of B cells Immune cell killing of leukemic monocytes
• PBMCs treated with combinations of IL-2 (10 ng/mL), anti-CD3 (0.1 ng/mL), and/or anti-CD28 (1 -100 ng/mL).
• Note the lag period (approx 96h) before proliferation and the concomitant clustering of the PBMCs. 
